Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Director Declan Doogan sold 128,058 shares of the business’s stock in a transaction dated Thursday, January 18th. The stock was sold at an average price of $26.95, for a total transaction of $3,451,163.10. Following the transaction, the director now owns 2,583,289 shares in the company, valued at $69,619,638.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Declan Doogan also recently made the following trade(s):
- On Wednesday, January 10th, Declan Doogan sold 40,362 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $27.69, for a total transaction of $1,117,623.78.
- On Friday, January 12th, Declan Doogan sold 121,942 shares of Biohaven Pharmaceutical stock. The stock was sold at an average price of $26.78, for a total transaction of $3,265,606.76.
Shares of Biohaven Pharmaceutical Holding Co Ltd (NYSE BHVN) traded down $0.69 during trading on Friday, hitting $29.71. 419,481 shares of the stock traded hands, compared to its average volume of 431,276. Biohaven Pharmaceutical Holding Co Ltd has a fifty-two week low of $17.00 and a fifty-two week high of $39.51. The firm has a market cap of $1,070.00 and a PE ratio of -5.69.
Biohaven Pharmaceutical (NYSE:BHVN) last issued its earnings results on Tuesday, November 14th. The company reported ($1.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.22) by $0.03. sell-side analysts expect that Biohaven Pharmaceutical Holding Co Ltd will post -6.4 earnings per share for the current year.
Several equities research analysts recently weighed in on BHVN shares. Piper Jaffray Companies set a $48.00 target price on shares of Biohaven Pharmaceutical and gave the stock a “buy” rating in a research note on Monday, December 11th. Needham & Company LLC reaffirmed a “buy” rating and set a $36.00 target price on shares of Biohaven Pharmaceutical in a research note on Wednesday, November 15th. BidaskClub downgraded shares of Biohaven Pharmaceutical from a “sell” rating to a “strong sell” rating in a research note on Tuesday, November 14th. Canaccord Genuity assumed coverage on shares of Biohaven Pharmaceutical in a report on Friday, December 15th. They set a “buy” rating and a $30.00 price target for the company. Finally, Zacks Investment Research upgraded shares of Biohaven Pharmaceutical from a “hold” rating to a “buy” rating and set a $25.00 price target for the company in a report on Monday, December 4th. Two investment analysts have rated the stock with a sell rating and six have assigned a buy rating to the company. Biohaven Pharmaceutical presently has an average rating of “Buy” and an average price target of $36.14.
Several institutional investors have recently modified their holdings of the company. Legal & General Group Plc acquired a new position in shares of Biohaven Pharmaceutical in the 3rd quarter valued at $119,000. Nationwide Fund Advisors acquired a new stake in Biohaven Pharmaceutical during the 3rd quarter worth $214,000. American International Group Inc. acquired a new stake in Biohaven Pharmaceutical during the 3rd quarter worth $251,000. State of Wisconsin Investment Board acquired a new stake in Biohaven Pharmaceutical during the 3rd quarter worth $262,000. Finally, Susquehanna International Group LLP acquired a new stake in Biohaven Pharmaceutical during the 3rd quarter worth $302,000. Institutional investors and hedge funds own 47.76% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Director Declan Doogan Sells 128,058 Shares” was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://ledgergazette.com/2018/02/12/declan-doogan-sells-128058-shares-of-biohaven-pharmaceutical-holding-co-ltd-bhvn-stock.html.
Biohaven Pharmaceutical Company Profile
Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.